ABT vs. AZN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABT and AZN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
AZN stands out with 432.07 billion USD in market value—about 1.87× ABT’s market cap of 231.49 billion USD.
ABT’s beta of 0.74 points to much larger expected swings compared to AZN’s calmer 0.18, suggesting both higher upside and downside potential.
AZN is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ABT, which is purely domestic.
| Symbol | ABT | AZN |
|---|---|---|
| Company Name | Abbott Laboratories | AstraZeneca PLC |
| Country | US | GB |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Drug Manufacturers - General |
| CEO | Mr. Robert B. Ford | Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. |
| Price | 133.05 USD | 69.68 USD |
| Market Cap | 231.49 billion USD | 432.07 billion USD |
| Beta | 0.74 | 0.18 |
| Exchange | NYSE | NASDAQ |
| IPO Date | March 17, 1980 | May 12, 1993 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ABT and AZN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
For a detailed comparison of valuation metrics between ABT and AZN, please refer to the table below.
| Symbol | ABT | AZN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 17.22 | 27.80 |
| Forward PEG Ratio (TTM) | 1.73 | 2.50 |
| Price-to-Sales Ratio (P/S, TTM) | 5.47 | 3.93 |
| Price-to-Book Ratio (P/B, TTM) | 2.48 | 5.26 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 34.77 | 22.33 |
| EV-to-EBITDA (TTM) | 22.97 | 13.68 |
| EV-to-Sales (TTM) | 5.63 | 4.41 |
| EV-to-Free Cash Flow (TTM) | 35.78 | 25.07 |
Dividend Comparison
Both ABT and AZN offer similar dividend yields (1.71% vs. 1.39%), indicating comparable approaches to balancing income and growth.
| Symbol | ABT | AZN |
|---|---|---|
| Dividend Yield (TTM) | 1.71% | 1.39% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ABT and AZN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- AZN’s current ratio of 0.90 indicates its assets may not cover near-term debts, whereas ABT at 1.78 maintains healthy liquidity.
- AZN posts a quick ratio of 0.70, indicating limited coverage of short-term debts from its most liquid assets—while ABT at 1.27 enjoys stronger liquidity resilience.
| Symbol | ABT | AZN |
|---|---|---|
| Current Ratio (TTM) | 1.78 | 0.90 |
| Quick Ratio (TTM) | 1.27 | 0.70 |
| Debt-to-Equity Ratio (TTM) | 0.14 | 0.77 |
| Debt-to-Assets Ratio (TTM) | 0.16 | 0.30 |
| Interest Coverage Ratio (TTM) | 15.39 | 7.95 |